

# **Tata Chemicals**

Buy

# **Estimate change TP change**

**Rating change** 

Motilal Oswal values your support in the Asiamoney Brokers Poll 2020 for India Research, Sales and Trading team. We request your ballot.



Bloomberg	TTCH IN
Equity Shares (m)	255
M.Cap.(INRb)/(USDb)	75.9 / 1
52-Week Range (INR)	344 / 197
1, 6, 12 Rel. Per (%)	-6/-1/21
12M Avg Val (INR M)	570

### Financials & Valuations (INR b)

		•	
Y/E Mar	2020	2021E	2022E
Sales	103.6	100.4	113.1
EBITDA	19.5	16.8	21.1
PAT	8.1	4.8	8.5
EBITDA (%)	18.8	16.7	18.7
EPS (INR)	31.7	18.7	33.5
EPS Gr. (%)	(6.4)	(40.8)	78.9
BV/Sh. (INR)	506	511	529
Ratios			
Net D/E	0.3	0.3	0.3
RoE (%)	6.4	3.7	6.4
RoCE (%)	6.7	4.2	5.9
Payout (%)	42.7	72.2	45.9
Valuations			
P/E (x)	9.4	15.9	8.9
EV/EBITDA (x)	6.4	7.4	5.7
Div Yield (%)	3.7	3.7	4.2
FCF Yield (%)	(5.5)	7.8	11.7

# Shareholding pattern (%)

As On	Jun-20	Mar-20	Jun-19
Promoter	34.6	34.6	30.6
DII	32.0	34.2	37.7
FII	11.2	9.3	10.7
Others	22.2	21.9	21.0

#### **CMP: INR298** TP: INR368 (+24%)

# North America drags down overall performance

# Performance below expectations

- Tata Chemicals (TTCH)'s operating performance was muted across geographies (barring Europe) and in Rallis. This was primarily led by North America (NA), wherein EBITDA declined 81% YoY on lower volume offtake.
- The Soda Ash segment's performance was impacted by a reduction in demand from the end user industry (largely for flat and container glass). Factoring the miss in our estimates and a weak end user industry demand scenario, we cut our EBITDA estimates by 14%/6% for FY21/FY22 and arrive at an SOTP-based TP of INR368. Maintain Buy.

# **Europe and Rallis on strong footing**

- TTCH's consolidated revenue declined 9% YoY to INR23.5b (est.: INR24.7b), with the EBITDA margin contracting 460bp YoY to 15.3% (est.: 18.3%). This was primarily on account of the absence of operating leverage and higher RM cost, offset by lower freight and power costs. EBITDA de-grew 30% YoY to INR3.6b (est.: INR4.5b). Adj. PAT declined 92% YoY to INR133m (est.: INR1,824m); decline in adj. PAT was higher due to higher interest cost (+25% YoY), higher depreciation (+17% YoY), and lower other income (-32% YoY). Other income declined on lower interest income and dividends.
- India's standalone operations revenue/EBITDA declined 13%/18%. This was on account of a 28%/22% drop in soda ash/bicarb volumes and lower realization, offset by 26% volume growth in salt. The Basic Chemistry segment's revenue/EBIT declined by 14%/ 22% during the quarter.
- In North America (NA), revenue declined 27% YoY due to a 28% drop in volumes (exports / domestic volumes declined 45% / 13% YoY). Additionally, realization also fell ~7% YoY (to USD211/mt), whereas currency benefit of 9% led to an overall realization increase of 2% YoY (to INR15,995/mt). EBITDA/mt plunged by 76% YoY (to USD12), with EBITDA contracting 81% YoY (to INR350m) due to negative operating leverage. PBT loss stood at INR1,190m v/s profit of INR910m last year as the company reported a onetime cost of INR380m toward the refinancing of US borrowings.
- In Europe, revenue grew a mere 3% YoY; EBITDA was up 56% YoY on a change in the sales mix (lower trading volumes; bicarb volumes were up 25% YoY, whereas soda ash declined 9% YoY). Blended EBITDA/mt increased by 44% YoY (to GBP32).
- Africa's soda ash volumes/realizations (in USD) declined 10%/20%, leading to a revenue/EBITDA decrease of 21%/50%.
- Rallis' revenue increased 6% YoY on account of higher volumes in major products; EBITDA was up 31% YoY.

Sumant Kumar (Sumant.Kumar@motilaloswal.com)

# Highlights from management commentary

- Aggregate capex was earlier guided for INR24b for Mithapur; INR6b of this has already been spent, and the remaining INR18b would be spent over the next 2– 2.5 years.
- Gross debt was at INR70b as of Jun'20 v/s INR77b as of March'20. Net debt stood at INR37.6b as of June'20 v/s INR40.4b as of March'20.
- Many plants in China have extended their maintenance shutdowns. However, historically, plants that have been in maintenance shutdown for more than a year mostly do not come back into the system. 2–5mmt of capacity is expected to be reduced from the China market.

#### Valuation and view

- Plants across locations are now operational. However, the key bottleneck is in terms of demand from the end user industry, which is dragging down performance. Demand for soda ash is under pressure as demand for flat glass, which finds application in the Real Estate and Auto sectors, remains muted. This is likely to weigh on performance in the near term.
- TTCH is incurring capex of INR24b at its Mithapur plant for various categories, expected to come on line in a phased manner. TTCH's cash-cow business (soda ash and sodium bicarbonate) is expected to remain relatively stable; cash generated from the business would be partially deployed toward the Specialty Chemicals segment.
- Factoring the miss in our estimates and a weak end user industry demand scenario, we cut our EBITDA estimates by 14%/6% for FY21/FY22 and arrive at an SOTP-based TP of INR368. Maintain Buy.

		=>4				=>4					<u> </u>	
Y/E March		FY:	20			FY	21		_		FY21	Var
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE	FY20	FY21	1QE	%
Net Sales	25,840	27,670	26,234	23,781	23,482	26,698	25,611	24,632	1,03,492	1,00,422	24,684	-5
YoY Change (%)	-5.8	-6.5	2.1	-7.2	-9.1	-3.5	-2.4	3.6	-4.5	-3.0	-14.8	
Total Expenditure	20,691	22,063	21,499	19,779	19,884	22,264	21,136	20,328	84,033	83,612	20,162	
EBITDA	5,149	5,607	4,735	4,002	3,598	4,434	4,475	4,304	19,492	16,810	4,522	-20
Margins (%)	19.9	20.3	18.0	16.8	15.3	16.6	17.5	17.5	18.8	16.7	18.3	
Depreciation	1,627	1,658	1,641	1,739	1,899	1,910	1,920	1,930	6,665	7,659	1,745	
Interest	941	861	755	855	1,179	799	770	760	3,419	3,507	875	
Other Income	869	923	586	756	587	650	586	756	3,111	2,578	808	
PBT before EO expense	3,450	4,011	2,925	2,163	1,107	2,375	2,371	2,369	12,519	8,222	2,710	
Extra-Ord expense	44	0	208	-62,367	0	0	0	0	-61,997	0	0	
PBT	3,406	4,011	2,717	64,531	1,107	2,375	2,371	2,369	74,517	8,222	2,710	
Tax	1,116	255	676	193	358	582	581	580	2,197	2,101	664	
Rate (%)	32.8	6.4	24.9	0.3	32.3	24.5	24.5	24.5	2.9	25.6	24.5	
MI & Profit/Loss of Asso. Cos.	756	799	580	123	616	407	201	124	2,257	1,348	222	
Reported PAT	1,535	2,957	1,462	64,215	133	1,386	1,589	1,665	70,063	4,773	1,824	
Adj PAT	1,579	2,957	1,670	1,847	133	1,386	1,589	1,665	8,066	4,773	1,824	-93
YoY Change (%)	-26.2	-8.1	-19.6	-24.3	-91.6	-53.1	-4.8	-9.9	-6.4	-40.8	-15.8	
Margins (%)	6.1	10.7	6.4	7.8	0.6	5.2	6.2	6.8	7.8	4.8	7.4	

Sum of four quarters for FY20 would not add up to the full year's numbers as past numbers have been restated


**Key Performance Indicators** 

Y/E March		FY2	0			FY2	1		FY20	FY21
Consolidated	1Q	2Q	3Q	4Q	1QE	2QE	3QE	4QE		
Sales Volume (000'mt)										
North America	539	570	569	553	387	456	512	536	2,231	1,892
Europe	92	104	97	101	92	105	98	103	394	398
Africa	63	74	40	75	57	68	72	77	252	274
EBITDA/mt										
North America (USD)	50.5	46.6	45.7	52.0	11.9	25.5	37.0	43.0	49.0	30.8
Europe (GBP)	21.9	49.2	53.1	56.0	31.6	40.0	50.0	50.0	40.4	43.1
Africa (USD)	45.7	52.2	-32.0	20.7	23.1	25.0	25.0	25.0	29.9	24.6
Cost Breakup										
RM Cost (% of sales)	17.4	23.2	19.7	15.1	25.2	23.0	19.5	15.0	19.0	20.6
Staff Cost (% of sales)	13.3	12.2	13.5	14.3	14.3	12.2	12.5	13.0	13.3	13.0
Power and Fuel Cost (% of sales)	13.6	12.3	14.3	16.0	12.1	12.3	14.3	16.0	14.0	13.7
Freight and Distribution Cost (% of sales)	15.4	14.1	14.5	16.2	13.3	14.2	14.5	16.4	15.0	14.6
Other Cost (% of sales)	20.3	17.8	20.0	21.6	19.7	21.6	21.7	22.1	19.9	21.3
Gross Margins (%)	82.6	76.8	80.3	84.9	74.8	77.0	80.5	85.0	81.0	79.4
EBITDA Margins (%)	19.9	20.3	18.0	16.8	15.3	16.6	17.5	17.5	18.8	16.7
EBIT Margins (%)	13.6	14.3	11.8	9.5	7.2	9.5	10.0	9.6	12.4	9.1


 $Motilal\ Oswal$ 

# **Key exhibits**

**Exhibit 1: Consolidated revenue trend** 




**Exhibit 2: Consolidated EBITDA trend** 



Source: Company, MOFSL

Source: Company, MOFSL

Exhibit 3: Consolidated adj. PAT trend



Source: Company, MOFSL

**Exhibit 4: Consolidated segmental revenue trend** 

INR m	1QFY20	4QFY20	1QFY21	%YoY	%QoQ
Revenue	· · · · · · · · · · · · · · · · · · ·		,		
Basic Chemistry Products	19,493	19,987	16,723	-14.20%	-16.30%
Specialty Products	6,337	3,776	6,759	6.60%	79.00%
Less: Inter-segment revenue	25	9	27		
Add: Unallocated	36	28	27		
Total Revenue	25,840	23,781	23,482	-9.10%	-1.30%

Source: Company, MOFSL

**Exhibit 5: Consolidated segmental EBIT trend** 

INR m	1QFY20	4QFY20	1QFY21	%YoY	%QoQ
EBIT					
Basic Chemistry Products	3,182	3,544	1,117	-64.9%	-68.5%
Margin %	16.3%	17.7%	6.7%		
Specialty Products	755	-368	934	23.6%	-354.0%
Margin %	11.9%	-9.7%	13.8%		
Total EBIT	3,937	3,176	2,051		
Less: Finance Cost	941	855	1,179		
Less: Unallocated (Income)/Expense	-453	158	-235		
PBT	3,450	2,163	1,107	-67.9%	-48.9%

Source: Company, MOFSL

 $Motilal \ Oswal$ 

**Exhibit 6: Standalone operational performance trend** 

INR m	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20	1QFY21	%YoY	%QoQ
Soda Ash Sales Volume ('000mt)	171	172	182	163	154	158	159	118	-28%	-26%
Sodium Bicarbonate Sales Volume ('000mt)	25	24	28	27	25	27	26	21	-22%	-19%
Salt Sales Volume ('000mt)	255	293	261	237	295	301	290	298	26%	3%
Realization - Basic Chemistry Products (INR/mt)	16,376	15,261	18,107	16,576	14,604	15,005	14,808	14,007	-16%	-5%
Net Sales	10,136	7,570	8,610	7,190	7,041	7,560	7,340	6,280	-13%	-14%
EBITDA	2,562	1,650	1,810	1,890	1,941	1,950	1,400	1,560	-17%	11%
EBITDA (%)	25%	21.8%	21.0%	26.3%	27.6%	25.8%	19.1%	24.8%		
PBT	3,805	1,324	2,748	2,563	2,398	1,671	63,791	1,423	-44%	-98%
PAT	2,951	890	1,722	2,056	2,346	1,371	1,179	1,088	-47%	-8%

Source: Company, MOFSL

**Exhibit 7: North America operational performance trend** 

INR m	2QFY19	<b>3QFY19</b>	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20	1QFY21	%YoY	%QoQ
Soda ash Utilization (%)	90%	91%	86%	88%	91%	94%	91%	60%		
Sales Volume ('000mt)	555	569	550	539	570	569	553	387	-28%	-30%
Realization (INR/mt)	15,459	15,624	15,818	15,677	15,544	15,325	14,467	15,995	2%	11%
Realization (USD/mt)	226	224	226	226	222	218	204	211	-7%	3%
EBITDA/mt (USD)	45	43	53	50	47	46	52	12	-76%	-77%
Net Sales	8,580	8,890	8,700	8,450	8,860	8,720	8,000	6,190	-27%	-23%
EBITDA	1,700	1,710	2,050	1,890	1,860	1,830	2,040	350	-81%	-83%
EBITDA (%)	20%	19.2%	23.6%	22.4%	21.0%	21.0%	25.5%	5.7%		
PBT	890	800	2,340	910	860	790	920	-1,190	-231%	-229%
PAT	450	350	2,070	470	460	400	790	-1,070	-328%	-235%

Source: Company, MOFSL

**Exhibit 8: Europe operational performance trend** 

INR m	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20	1QFY21	%YoY	%QoQ
Sales Volume ('000mt)	109	110	104	92	104	97	101	92	0%	-9%
Realization (INR/mt)	32,385	33,727	36,635	33,370	32,404	35,876	36,139	34,348	3%	-5%
Realization (GBP/mt)	355	368	399	373	368	402	401	356	-5%	-11%
EBITDA/mt (GBP)	33	14	28	22	49	53	56	32	44%	-44%
Net Sales	3,530	3,710	3,810	3,070	3,370	3,480	3,650	3,160	3%	-13%
EBITDA	330	140	270	180	450	460	510	280	56%	-45%
EBITDA (%)	9.3%	3.8%	7.1%	5.9%	13.4%	13.2%	14.0%	8.9%		
PBT	60	-350	-300	-150	80	80	130	-150	0%	-215%
PAT	60	-350	-150	-150	80	80	130	-150	0%	-215%

Source: Company, MOFSL

**Exhibit 9: Africa operational performance trend** 

INR m	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20	1QFY21	%YoY	%QoQ
Soda ash Utilization (%)	87%	89%	94%	90%	66%	72%	71%	65%		
Sales Volume ('000mt)	72	80	79	63	74	40	75	57	-10%	-24%
Realization (INR/mt)	17,778	18,000	17,848	20,000	18,784	19,750	15,333	17,544	-12%	14%
Realization (USD/mt)	259	258	255	288	269	281	216	231	-20%	7%
EBITDA/mt (USD)	26	52	56	46	52	-32	21	23	-49%	12%
Net Sales	1,280	1,440	1,410	1,260	1,390	790	1,150	1,000	-21%	-13%
EBITDA	130	290	310	200	270	-90	110	100	-50%	-9%
EBITDA (%)	10%	20.1%	22.0%	15.9%	19.4%	-11.4%	9.6%	10.0%		
PBT	40	190	230	90	160	-20	-40	-20	-122%	-50%
PAT	40	190	230	90	160	-20	-40	-20	-122%	-50%

Source: Company, MOFSL

Motilal Oswal

**Exhibit 10: Capacity expansion timeline** 




Source: Company, MOFSL

Exhibit 11: Region-wise performance during the quarter

Business Units	Key Highlights	TCL Split between Domestic & Exports Vols. (In Kts)	Impact on TCL Performance
India	Demand is returning, but growth subdued Flat Glass industry tend to de grow, it's operations started after 3 months of Lockdown Good demand from Soaps and Detergents industry Container glass fared better than flat glass but still with negative growth	163 118 Q1 FY20 Q1 FY21	Volumes ↓ ~27%
US US	Domestic Flat Glass demand drop by 20% Export demand significantly low driven by Flat glass line closures Container glass demand in export markets also soft Domestic Container Glass demand less impacted	251 288 138 250 Q1 FY20 Q1 FY21	Domestic Volume ↓~13% Export Volume ↓~45%
UK	Container Glass demand remained relatively stable; minor impact on account of closure of hospitality sector  Detergent and Bicarb demand grew  Flat glass lines closed; TCE has negligible sales into that sector	68 62 Q1 FY20 Q1 FY21	Volumes ↓~9%
<b>A</b> frica	Container Glass demand remained relatively stable	45 18 41 17 Q1 FY20 Q1 FY21	Domestic Volume ↓~6% Export Volume ↓~10%
		Exports Domestic	

Source: Company, MOFSL

Exhibit 12: Borrowing position as of June 2020



Source: Company, MOFSL

Exhibit 13: Global soda ash demand situation



#### Market Size shrinks; Led by Flat Glass Industry

- Capacity is estimated to be operating at ~80% vs. historic of ~86%; Demand reduction of 6% vs 2019
- Reduction in demand from Flat Glass Industry is estimated to be  $^{\sim}18\%$
- Soaps & Detergents less impacted with estimated growth of ~3%
- Solar Glass in Asia continues to grow
- Container glass and Other glass is down by 3% but recovering
- Spot prices already seeing a decline, contract prices may follow soon





# Conference call highlights

# **India standalone operations**

- Good demand was witnessed for Soda Ash from the Soaps and Detergents segments as they are classified as essential commodities. However, this was offset by weak demand in the Flat Glass (mainly from Automotive and Real Estate) and Container Glass segments throughout the lockdown period. But, demand is slowly returning to normal in these segments.
- Salt manufacturing in Mithapur continues to expand. Production and sales were the highest in the first quarter, with no supply disruption seen throughout the lockdown.
- Limited operations commenced in Mambattu, Nellore (Andhra Pradesh) and Cuddalore (Tamil Nadu) in May'20 following the relaxation of local restrictions; the facilities are currently meeting customer requirements.
- The Nutritional Solutions business witnessed slower demand offtake, yet received good traction from health-focused companies. It further commenced exports to the Southeast Asian markets, with encouraging customer response.
- The Silica business posted good demand in food and non-food grade silica from the Essential Goods segment, although demand from the Tyre and Automotive segments was muted.
- The company introduced InsperiCo, the world's first branded recycled cobalt, extracted from recycling lithium-ion batteries, contributing to a circular economy.

# **North America operations**

- During the quarter, the export market in the US witnessed a steep drop of 45% v/s PY. Demand from the export market was significantly low in the Flat Glass segment across the globe.
- Completed US operations' debt facilities, due in June and August 2020, were refinanced with new facilities at Valley Holdings, Inc. (USD100m) and Tata Chemicals North America (USD275m).
- High fixed cost, coupled with a reduction in export prices, has led to a fall in margins and realizations. The US domestic market has higher realization than the export market.
- The contribution margin is expected to be roughly around 55%.
- An additional USD5m (INR380m) cost emerged during the quarter, which was a one-time expense (re-financing in order to move to a different and cheaper financing structure).

 Volume decline was majorly due to lower demand from customers. Port closures were only seen in the Southeast Asia market; 2Q is expected to fare better than 1Q.

# **UK operations**

 UK operations did not suffer any significant disruption in production or sales, with customer demand remaining as expected. Sodium Bicarbonate posted healthy growth in demand across user sectors.

# **Africa operations**

- Kenya did not see any disruption in production, but dispatches to the India market and Southeast Asian countries were disrupted due to lockdown in these countries
- In Magadi, a drop in product price, coupled with no major fall in corresponding input prices, affected the business.

# Other highlights

# Capex

- Expansion in the salt plant in India to 1.4mmt from 1mmt is on track.
- Aggregate capex was earlier guided for INR24b for Mithapur; INR6b of this has already been spent, and the remaining INR18b would be spent over the next 2–2.5 years.
- There will be no major drop in capex spend; INR1–1.5b less expenditure v/s last year is projected.
- Nutraceutical: The factory could expand four times the current size and see strong customer demand.
- Silica: Supply to the Tyre industry was constrained due to the lack of capacity. The Tamil Nadu government allocated additional land last month (July) that would be utilized for capacity expansion.
- China market: Many plants in China have extended their maintenance shutdowns. However, historically, plants that have been in maintenance shutdown for more than a year mostly do not come back into the system. 2– 5mmt of capacity is expected to be reduced from the China market.
- Inventory with producers in India is estimated at 150,000–200,000mt. Globally, it is estimated at 0.9–1mmt.

# **Valuation**

- Plants across locations are now operational. However, the key bottleneck is in terms of demand from the end user industry, which is dragging down performance. Demand for soda ash is under pressure as demand for flat glass, which finds application in the Real Estate and Auto sectors, remains muted. This is likely to weigh on performance in the near term.
- TTCH is incurring capex of INR24b at its Mithapur plant for various categories, expected to come on line in a phased manner. TTCH's cash-cow business (soda ash and sodium bicarbonate) is expected to remain relatively stable; cash generated from the business would be partially deployed toward the Specialty Chemicals segment.
- Factoring the miss in our estimates and a weak end user industry demand scenario, we cut our EBITDA estimates by 14%/6% for FY21/FY22 and arrive at an SOTP-based TP of INR368. Maintain Buy.

**Exhibit 14: Valuation methodology** 

				Multiple	EV/ MCAP (INR
Business	Methodology	Metrics	FY22	(x)	m)
Commodity (INR m)					
Inorganic Chemical India (Soda Ash & others) (Inc mfg Salt)	EV/EBITDA (x)	EBITDA	7,534	7.0	52,736
Tata Chemicals North America	EV/EBITDA (x)	EBITDA	7,097	7.0	49,680
Tata Chemicals Europe and Tata Chemicals Africa	EV/EBITDA (x)	EBITDA	2,760	5.0	13,799
Sub Total					1,16,215
Specialty and Consumer (INR m)					
Rallis India Ltd (Tata Chemicals hold 50%) (INR m)	20% discount to Current	Attributable	tributable 57,174		22,870
Railis Iliula Ltu (Tata Chemicais Ilolu 50%) (Ilvk III)	MCAP	Mcap	57,174	0.8	22,670
Total EV (INR m)					1,39,084
Less: Debt (INR m)					73,827
Less: Minority Interest (INR m)					7,638
Less: Pension Liability (INR m)					14,665
Add: Cash & Liquid investment (INR m)					37,234
Add: Value of quoted Investment (INR m)		Mcap	17,119	0.8	13,695
Target Mcap (INR m)					93,884
Outstanding share (m)					255
Target Price (INR)					368
CMP (INR)					298
Upside (%)					24%

Source: MOFSL

**Exhibit 15: Estimate change** 

•						
Earnings Change	Old		New		Change	
(INR m)	FY21E	FY22E	FY21E	FY22E	FY21E	FY22E
Revenue	1,04,478	1,17,784	1,00,422	1,13,082	-4%	-4%
EBITDA	19,531	22,379	16,810	21,096	-14%	-6%
Adj. PAT	7,299	9,414	4,773	8,538	-35%	-9%

Source: MOFSL

# **Financials and valuations**

Consolidated – Income Statement					_		(INR m)
Y/E March	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
Total Income from Operations	1,52,202	1,03,461	1,02,697	1,03,367	1,03,568	1,00,422	1,13,082
Change (%)	-13.4	-32.0	-0.7	0.7	0.2	-3.0	12.6
Total Expenditure	1,31,285	82,518	80,790	85,563	84,076	83,612	91,985
EBITDA	20,917	20,943	21,907	17,805	19,492	16,810	21,096
Margin (%)	13.7	20.2	21.3	17.2	18.8	16.7	18.7
Depreciation	5,261	5,122	5,180	5,685	6,665	7,659	7,807
EBIT	15,657	15,821	16,727	12,120	12,827	9,151	13,289
Int. and Finance Charges	5,255	2,973	3,256	3,537	3,419	3,507	2,993
Other Income	1,253	1,661	1,595	4,095	3,111	2,578	2,940
PBT bef. EO Exp.	11,655	14,510	15,066	12,677	12,519	8,222	13,237
EO Items	0	0	643	703	0	0	0
PBT after EO Exp.	11,655	14,510	15,709	13,381	12,519	8,222	13,237
Total Tax	2,484	3,460	601	2,744	2,197	2,101	3,243
Tax Rate (%)	21.3	23.8	3.8	20.5	17.5	25.6	24.5
Minority Interest	2,207	2,254	2,202	1,317	2,257	1,348	1,456
Reported PAT - Continuing Ops.	6,964	8,796	12,906	9,319	8,066	4,773	8,538
Adjusted PAT - Continuing Ops.	6,964	8,796	12,263	8,615	8,066	4,773	8,538
Change (%)	-12.5	26.3	39.4	-29.7	-6.4	-40.8	78.9
Margin (%)	4.6	8.5	11.9	8.3	7.8	4.8	7.6
Reported PAT - Discontinuing Ops.	742	1,135	11,425	2,240	61,997	0	0
Reported PAT	7,706	9,931	24,331	11,559	70,063	4,773	8,538
Adjusted PAT	7,706	9,931	23,687	10,856	70,063	4,773	8,538
Consolidated – Balance Sheet							(INR m)
Y/E March	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
Equity Share Capital	2,548	2,548	2,548	2,548	2,548	2,548	2,548
Total Reserves	65,995	76,534	1,08,469	1,20,865	1,26,428	1,27,754	1,32,374
Net Worth	68,543	79,082	1,11,017	1,23,413	1,28,977	1,30,302	1,34,922
Minority Interest	25,985	26,239	27,172	29,147	7,638	7,638	7,638
Total Loans	90,904	70,483	64,180	61,430	77,020	75,810	73,827
Lease liability	0	0	0	0	1,880	1,880	1,880
Deferred Tax Liabilities	12,348	12,381	11,916	12,972	14,379	14,379	14,379
Capital Employed	1,97,780	1,88,185	2,14,284	2,26,961	2,29,894	2,30,009	2,32,646
Gross Block	1,20,671	1,20,011	1,26,061	1,38,124	1,61,488	1,68,488	1,78,488
Less: Accum. Deprn.	5,490	10,612	15,792	21,477	28,141	35,801	43,607
Net Fixed Assets	1,15,181	1,09,400	1,10,269	1,16,648	1,33,346	1,32,687	1,34,880
Goodwill on Consolidation	17,619	16,984	17,319	18,590	19,542	19,542	19,542
Capital WIP	5,015	3,331	4,089	7,738	8,350	8,500	8,500
Current Investments	94	2,205	918	22,523	16,010	16,010	16,010
Total Investments	21,879	27,931	28,683	56,425	43,060	43,060	43,060
Curr. Assets, Loans&Adv.	83,769	78,459	98,427	69,648	73,223	72,961	78,224
Inventory	19,319	13,861	14,623	17,256	18,692	19,714	20,426
Account Receivables	35,656	20,922	13,079	14,525	15,799	15,407	17,350
Cash and Bank Balance	12,654	16,648	44,830	19,522	20,795	19,764	21,224
Loans and Advances	16,140	27,028	25,895	18,346	17,937	18,076	19,224
Curr. Liability & Prov.	45,682	47,919	44,502	42,088	47,628	46,742	51,561
Account Payables	16,818	13,182	14,786	14,753	16,309	16,476	17,071
Other Current Liabilities	7,923	14,117	10,908	9,492	12,015	11,549	13,004
Provisions	20,941	20,621	18,808	17,843	19,304	18,718	21,486
Net Current Assets	38,086	30,540	53,925	27,560	25,595	26,219	26,663
	• -					•	

# **Financials and valuations**

Y/E March	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
Basic (INR)							
EPS	27.3	34.5	48.1	33.8	31.7	18.7	33.5
Cash EPS	48.0	54.6	68.5	56.1	57.8	48.8	64.1
BV/Share	269.0	310.3	435.7	484.3	506.1	511.3	529.5
DPS	10.0	11.0	22.0	12.5	11.0	11.0	12.5
Payout (%)	45.0	39.2	53.4	42.0	42.7	72.2	45.9
Valuation (x)							
P/E		8.6	6.2	8.8	9.4	15.9	8.9
Cash P/E		5.5	4.4	5.3	5.2	6.1	4.6
P/BV		1.0	0.7	0.6	0.6	0.6	0.6
EV/Sales		1.5	1.2	1.2	1.2	1.2	1.1
EV/EBITDA		7.3	5.5	7.0	6.4	7.4	5.7
Dividend Yield (%)		3.7	7.4	4.2	3.7	3.7	4.2
FCF per share		113.3	76.9	19.7	-16.3	23.2	34.8
Return Ratios (%)							
RoE	11.2	11.9	12.9	7.4	6.4	3.7	6.4
RoCE	8.9	8.6	10.9	7.2	6.7	4.2	5.9
Core RoCE	14.0	10.8	15.6	11.2	10.5	6.7	9.3
RoIC	8.6	8.1	11.6	6.9	7.0	4.3	6.3
Working Capital Ratios							
Fixed Asset Turnover (x)	1.3	0.9	0.8	0.7	0.6	0.6	0.6
Asset Turnover (x)	0.8	0.5	0.5	0.5	0.5	0.4	0.5
Inventory (Days)	119	244	304	315	347	347	347
Debtor (Days)	86	74	46	51	56	56	56
Creditor (Days)	103	232	307	269	302	290	290
Leverage Ratio (x)							
Current Ratio	1.8	1.6	2.2	1.7	1.5	1.6	1.5
Interest Cover Ratio	3.0	5.3	5.1	3.4	3.8	2.6	4.4
Net Debt/Equity	1.1	0.7	0.2	0.2	0.3	0.3	0.3
Consolidated – Cash Flow Statement							(INR m)
Y/E March	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
00/// 11 6 =	10.00=	46 - 46	45.000	4= 004	40.540		40.00=

Consolidated – Cash Flow Statement							(INR m)
Y/E March	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
OP/(Loss) before Tax	12,935	16,522	15,066	17,304	12,519	8,222	13,237
Depreciation	5,714	5,522	5,180	5,714	6,665	7,659	7,807
Interest & Finance Charges	5,946	4,645	1,661	3,653	308	929	53
Direct Taxes Paid	-3,645	-4,516	-601	-4,849	-2,197	-2,101	-3,243
(Inc)/Dec in WC	-652	12,103	4,797	-2,144	506	-1,656	1,016
CF from Operations	20,298	34,276	26,103	19,678	17,801	13,053	18,870
Others	3,022	1,033	643	-3,865	0	0	0
CF from Operating incl EO	23,319	35,309	26,746	15,813	17,801	13,053	18,870
(Inc)/Dec in FA	-6,865	-6,429	-7,142	-10,795	-21,962	-7,150	-10,000
Free Cash Flow	16,454	28,880	19,604	5,018	-4,161	5,904	8,870
(Pur)/Sale of Investments	-90	-2,064	-752	-19,711	13,364	0	0
Others	-337	588	1,595	10,924	-15,085	2,578	2,940
CF from Investments	-7,292	-7,905	-6,300	-19,582	-23,682	-4,572	-7,060
Issue of Shares	0	0	0	0	0	0	0
Inc/(Dec) in Debt	-6,098	-14,117	-6,303	-5,714	12,625	-1,210	-1,983
Interest Paid	-6,202	-4,456	-3,256	-2,939	-3,419	-3,507	-2,993
Dividend Paid	-3,820	-3,056	-6,895	-6,725	-3,448	-3,448	-3,918
Others	-1,897	-1,781	24,190	-6,162	1,396	-1,348	-1,456
CF from Fin. Activity	-18,017	-23,409	7,736	-21,540	7,154	-9,513	-10,349
Inc/Dec of Cash	-1,989	3,995	28,182	-25,309	1,273	-1,031	1,460
Opening Balance	14,643	12,654	16,649	44,831	19,522	20,795	19,764
Closing Balance	12,654	16,649	44,831	19,522	20,795	19,764	21,224

Numbers excludes performance of consumer segment (salt and others) from FY19 onwards

# NOTES

Explanation of Investment Rating					
Investment Rating	Expected return (over 12-month)				
BUY	>=15%				
SELL	<-10%				
NEUTRAL	< - 10 % to 15%				
UNDER REVIEW	Rating may undergo a change				
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation				

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOFSL is a subsidiary company of Passionate Investment Management Pvt. Ltd.. (PIMPL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at <a href="www.nseindia.com">www.nseindia.com</a>. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

# For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered brokerdealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

# Specific Disclosures

- MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- Research Analyst has not served as director/officer/employee in the subject company
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
  MOFSL has not received compensation for investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received any compensation or other benefits from third party in connection with the research report
- MOFSL has not engaged in market making activity for the subject company

13 3 August 2020

MOTILAL OSWAL Tata Chemicals

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months
- other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

### **Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

# **Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 71934200/ 022-71934263; Website <a href="https://www.motilaloswal.com">www.motilaloswal.com</a>. CIN no.: L67190MH2005PLC153397. Correspondence Office Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad(West), Mumbai-400 064. Tel No: 022 7188 1000.

Registration Nos.: Motilal Oswal Financial Services Limited (MOFSL)\*: INZ000158836(BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN - 146822; Investment Adviser: INA000007100; Insurance Corporate Agent: CA0579;PMS:INP000006712. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP000000670); PMS and Mutual Funds are offered through MOAMC which is group company of MOFSL. Motilal Oswal Financial Services Limited is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs,Insurance Products and IPOs.Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services is backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. Details of Compliance Officer: Name: Neeraj Agarwal, Email ID: na@motilaloswal.com, Contact No.:022-71881085.

\* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench.